IDACIO is a prescription medication that belongs to a class of drugs known as biosimilars, specifically designed to mimic the effects of the reference biologic, adalimumab. It is used in the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and certain forms of inflammatory bowel disease, such as Crohn's disease and ulcerative colitis. IDACIO works by targeting and inhibiting tumor necrosis factor (TNF), a substance in the body that causes inflammation and can lead to the symptoms associated with these conditions. By doing so, it helps to reduce inflammation, alleviate symptoms, and prevent further damage to the body. Like its reference product, IDACIO is administered through subcutaneous injection and is intended for use under the guidance of a healthcare professional.